doxercalciferol
Selected indexed studies
- Doxercalciferol alleviates UVB-induced HaCaT cell senescence and skin photoaging. (Int Immunopharmacol, 2024) [PMID:38104366]
- Doxercalciferol treatment of secondary hyperparathyroidism. (Ann Pharmacother, 2006) [PMID:17062838]
- Pharmacokinetics of vitamin D toxicity. (Am J Clin Nutr, 2008) [PMID:18689406]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Pharmacokinetics of vitamin D toxicity. (2008) pubmed
- Doxercalciferol alleviates UVB-induced HaCaT cell senescence and skin photoaging. (2024) pubmed
- Doxercalciferol treatment of secondary hyperparathyroidism. (2006) pubmed
- Doxercalciferol Alleviates Bone Deteriorations and Cartilage Degeneration in Aging Mice. (2020) pubmed
- Doxercalciferol, a pro-hormone of vitamin D, prevents the development of cardiac hypertrophy in rats. (2011) pubmed
- Clinical uses of 1-alpha-hydroxy-ergocalciferol. (2014) pubmed
- A new look at the most successful prodrugs for active vitamin D (D hormone): alfacalcidol and doxercalciferol. (2009) pubmed
- Converting to doxercalciferol capsules from intravenous paricalcitol or doxercalciferol. (2012) pubmed
- Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. (2004) pubmed
- New drug overview. Doxercalciferol. (1999) pubmed